230 related articles for article (PubMed ID: 35577034)
1. Efficacy and Safety of Lisdexamfetamine in Preschool Children With Attention-Deficit/Hyperactivity Disorder.
Childress AC; Lloyd E; Jacobsen L; Gunawardhana L; Johnson SA; Findling RL
J Am Acad Child Adolesc Psychiatry; 2022 Dec; 61(12):1423-1434. PubMed ID: 35577034
[TBL] [Abstract][Full Text] [Related]
2. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
3. A Long-Term, Open-Label Safety and Tolerability Study of Lisdexamfetamine Dimesylate in Children Aged 4-5 Years with Attention-Deficit/Hyperactivity Disorder.
Childress AC; Lloyd E; Johnson SA; Gunawardhana L; Arnold V
J Child Adolesc Psychopharmacol; 2022 Mar; 32(2):98-106. PubMed ID: 35230142
[No Abstract] [Full Text] [Related]
4. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
Findling RL; Childress AC; Cutler AJ; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
J Am Acad Child Adolesc Psychiatry; 2011 Apr; 50(4):395-405. PubMed ID: 21421179
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe.
Coghill DR; Banaschewski T; Nagy P; Otero IH; Soutullo C; Yan B; Caballero B; Zuddas A
CNS Drugs; 2017 Jul; 31(7):625-638. PubMed ID: 28667569
[TBL] [Abstract][Full Text] [Related]
6. Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder.
Childress AC; Findling RL; Wu J; Kollins SH; Wang Y; Martin P; Robertson B
J Child Adolesc Psychopharmacol; 2020 Apr; 30(3):128-136. PubMed ID: 32233956
[No Abstract] [Full Text] [Related]
7. Phase II/III Study of Lisdexamfetamine Dimesylate in Japanese Pediatric Patients with Attention-Deficit/Hyperactivity Disorder.
Ichikawa H; Miyajima T; Yamashita Y; Fujiwara M; Fukushi A; Saito K
J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):21-31. PubMed ID: 31718254
[No Abstract] [Full Text] [Related]
8. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.
Soutullo C; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Bloomfield R; Squires LA; Coghill DR
CNS Drugs; 2013 Sep; 27(9):743-51. PubMed ID: 23801529
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study.
Dittmann RW; Cardo E; Nagy P; Anderson CS; Bloomfield R; Caballero B; Higgins N; Hodgkins P; Lyne A; Civil R; Coghill D
CNS Drugs; 2013 Dec; 27(12):1081-92. PubMed ID: 23959815
[TBL] [Abstract][Full Text] [Related]
10. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
[TBL] [Abstract][Full Text] [Related]
11. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design.
Wigal T; Brams M; Gasior M; Gao J; Squires L; Giblin J;
Behav Brain Funct; 2010 Jun; 6():34. PubMed ID: 20576091
[TBL] [Abstract][Full Text] [Related]
12. A long-term open-label safety and effectiveness trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
Findling RL; Cutler AJ; Saylor K; Gasior M; Hamdani M; Ferreira-Cornwell MC; Childress AC
J Child Adolesc Psychopharmacol; 2013 Feb; 23(1):11-21. PubMed ID: 23410138
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study.
Babcock T; Dirks B; Adeyi B; Scheckner B
BMC Pharmacol Toxicol; 2012 Dec; 13():18. PubMed ID: 23254273
[TBL] [Abstract][Full Text] [Related]
14. Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder.
Dittmann RW; Cardo E; Nagy P; Anderson CS; Adeyi B; Caballero B; Hodgkins P; Civil R; Coghill DR
CNS Drugs; 2014 Nov; 28(11):1059-69. PubMed ID: 25038977
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.
Biederman J; Krishnan S; Zhang Y; McGough JJ; Findling RL
Clin Ther; 2007 Mar; 29(3):450-63. PubMed ID: 17577466
[TBL] [Abstract][Full Text] [Related]
16. Long-term study of lisdexamfetamine dimesylate in Japanese children and adolescents with attention-deficit/hyperactivity disorder.
Ichikawa H; Miyajima T; Yamashita Y; Fujiwara M; Fukushi A; Saito K
Neuropsychopharmacol Rep; 2020 Mar; 40(1):52-62. PubMed ID: 31814294
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study.
Findling RL; Ginsberg LD; Jain R; Gao J
J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):649-62. PubMed ID: 20035583
[TBL] [Abstract][Full Text] [Related]
18. Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study.
Adler LA; Dirks B; Deas P; Raychaudhuri A; Dauphin M; Saylor K; Weisler R
BMC Psychiatry; 2013 Oct; 13():253. PubMed ID: 24106804
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
Najib J
Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
[TBL] [Abstract][Full Text] [Related]
20. The effects of lisdexamfetamine dimesylate on emotional lability in children 6 to 12 years of age with ADHD in a double-blind placebo-controlled trial.
Childress AC; Arnold V; Adeyi B; Dirks B; Babcock T; Scheckner B; Lasser R; Lopez FA
J Atten Disord; 2014 Feb; 18(2):123-32. PubMed ID: 22740112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]